|
rs2431689
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Rs17057846, rs1582417, and rs2431689 polymorphisms were associated with prognosis of astrocytoma, and rs1582417, rs17057846, and rs58747524 variants were associated with the survival rate in patients with low-grade glioma (I to II).
|
31513017 |
2020 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma.
|
30972500 |
2019 |
|
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma.
|
30972500 |
2019 |
|
rs12594
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cox regression analysis shows that RYR2 rs12594 AA genotype and AG genotype were associated with OS of astrocytoma (AG genotype: HR = 1.62, 95% CI 1.04-2.53, p = 0.034; AA genotype: HR = 1.70, 95% CI 1.08-2.68, p = 0.021).
|
31440994 |
2019 |
|
rs16835904
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Stratified analysis shows that RYR2 rs16835904 TC-TT genotype facilitated the risk of astrocytoma in male (OR = 1.93, 95% CI 1.15-3.24, p = 0.011).
|
31440994 |
2019 |
|
rs17522122
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whereas, rs4261436 (HR = 0.70, p = 0.045) and rs17522122 (HR = 0.75, p = 0.016) were associated with better prognosis of astrocytoma.
|
31759389 |
2019 |
|
rs2378456
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In recessive model, the patients with LPP rs2378456 CC genotype increased the risk of astrocytoma (OR = 1.43, 95% CI 1.01-2.02, p = 0.042).
|
31440994 |
2019 |
|
rs4261436
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whereas, rs4261436 (HR = 0.70, p = 0.045) and rs17522122 (HR = 0.75, p = 0.016) were associated with better prognosis of astrocytoma.
|
31759389 |
2019 |
|
rs7115578
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs7115578 AG genotype represented a poorer prognosis of glioma (HR = 1.24, P=0.033) and astrocytoma (log-rank P=0.037, HR = 1.31, P=0.036).
|
31652449 |
2019 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma.
|
28801347 |
2018 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the subgroup of 142 glioma patients characterized by IDH1-R132H status, METT/N ratio demonstrated a significant prognostic impact in IDH1-R132H wildtype astrocytomas and glioblastoma (P = 0.001).
|
29016947 |
2018 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Because many ALT tumors express the mutant isocitrate dehydrogenase IDH1 R132H, including all lower grade astrocytomas and secondary glioblastoma, we examined a hypothesized role for IDH1 R132H in driving the ALT phenotype during gliomagenesis.
|
29545335 |
2018 |
|
rs113488022
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis.
|
29902580 |
2018 |
|
rs121913377
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis.
|
29902580 |
2018 |
|
rs118101777
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma.
|
28801347 |
2018 |
|
rs5050
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma.
|
30383794 |
2018 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, an in-depth characterization of IDH1 R132H mutations were assessed by immunohistochemistry in 55 paired primary-recurrent astrocytomas tissues, including 5 paired primary pilocytic astrocytoma (pPA, WHO grade I), 35 paired primary low grade astrocytoma (pLGA, WHO grade II and III) and 15 paired primary high grade astrocytoma (pHGA/ Glioblastoma, WHO grade IV).
|
28928859 |
2017 |
|
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
No IDH1-R132H mutation was detected in 2 of 2 (0%) astrocytomas by immunohistochemistry.
|
26990854 |
2016 |
|
rs1057519903
|
|
T |
0.720 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs1057519897
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs1057519898
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs1057519899
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs121918464
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs121918465
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs121918465
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |